Avalo Therapeutics, Inc. - Common Stock (AVTX)

CUSIP: 05338F306

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock
Shares outstanding
22,946,429
Total 13F shares
7,843,040
Share change
-412,018
Total reported value
$39,137,186
Price per share
$4.99
Number of holders
35
Value change
-$2,087,558
Number of buys
12
Number of sells
14

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Avalo Therapeutics, Inc. - Common Stock (AVTX) as of Q2 2025

As of 30 Jun 2025, Avalo Therapeutics, Inc. - Common Stock (AVTX) was held by 35 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 7,843,040 shares. The largest 10 holders included BVF INC/IL, Nantahala Capital Management, LLC, ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Affinity Asset Advisors, LLC, Deep Track Capital, LP, Commodore Capital LP, TCG Crossover Management, LLC, BANK OF AMERICA CORP /DE/, and RWA WEALTH PARTNERS, LLC. This page lists 35 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
33
Q2 2025 holders
35
Holder diff
2
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 Value $ Q2 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.